Travel distance and stereotactic body radiotherapy for localized prostate cancer.
Brandon A MahalYu-Wei ChenRoshan V SethiOscar A PadillaDavid D YangJanice ChavezVinayak MuralidharJim C HuFelix Y FengKaren E HoffmanNeil E MartinDaniel E SprattJames B YuPeter F OrioPaul L NguyenPublished in: Cancer (2017)
Definitive prostate SBRT use increased more than 3-fold since 2004, with a significant increase in use coinciding with early reports of short-term efficacy. Long-distance travel for treatment was associated with greater than twice the odds of receipt of definitive prostate SBRT compared with short-distance travel, suggesting that treatment decisions with unknown long-term clinical implications may be strongly driven by sociodemographic factors. Cancer 2018;124:1141-9. © 2017 American Cancer Society.